Edwards Lifesciences Long Term Debt 2010-2022 | EW
Edwards Lifesciences long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
- Edwards Lifesciences long term debt for the quarter ending December 31, 2022 was $0.596B, a 0.1% increase year-over-year.
- Edwards Lifesciences long term debt for 2022 was $0.596B, a 0.1% increase from 2021.
- Edwards Lifesciences long term debt for 2021 was $0.596B, a 0.12% increase from 2020.
- Edwards Lifesciences long term debt for 2020 was $0.595B, a 0.1% increase from 2019.
Edwards Lifesciences Annual Long Term Debt
(Millions of US $) |
| 2022 |
$596 |
| 2021 |
$596 |
| 2020 |
$595 |
| 2019 |
$594 |
| 2018 |
$594 |
| 2017 |
$438 |
| 2016 |
$822 |
| 2015 |
$597 |
| 2014 |
$598 |
| 2013 |
$593 |
| 2012 |
$189 |
| 2011 |
$150 |
| 2010 |
$ |
| 2009 |
$90 |
Edwards Lifesciences Quarterly Long Term Debt
(Millions of US $) |
| 2022-12-31 |
$596 |
| 2022-09-30 |
$596 |
| 2022-06-30 |
$596 |
| 2022-03-31 |
$596 |
| 2021-12-31 |
$596 |
| 2021-09-30 |
$596 |
| 2021-06-30 |
$595 |
| 2021-03-31 |
$595 |
| 2020-12-31 |
$595 |
| 2020-09-30 |
$595 |
| 2020-06-30 |
$595 |
| 2020-03-31 |
$595 |
| 2019-12-31 |
$594 |
| 2019-09-30 |
$594 |
| 2019-06-30 |
$594 |
| 2019-03-31 |
$594 |
| 2018-12-31 |
$594 |
| 2018-09-30 |
$594 |
| 2018-06-30 |
$594 |
| 2018-03-31 |
$456 |
| 2017-12-31 |
$438 |
| 2017-09-30 |
$1,034 |
| 2017-06-30 |
$1,017 |
| 2017-03-31 |
$848 |
| 2016-12-31 |
$822 |
| 2016-09-30 |
$601 |
| 2016-06-30 |
$603 |
| 2016-03-31 |
$602 |
| 2015-12-31 |
$597 |
| 2015-09-30 |
$605 |
| 2015-06-30 |
$600 |
| 2015-03-31 |
$603 |
| 2014-12-31 |
$598 |
| 2014-09-30 |
$596 |
| 2014-06-30 |
$598 |
| 2014-03-31 |
$725 |
| 2013-12-31 |
$593 |
| 2013-09-30 |
$532 |
| 2013-06-30 |
$227 |
| 2013-03-31 |
$193 |
| 2012-12-31 |
$189 |
| 2012-09-30 |
$175 |
| 2012-06-30 |
$185 |
| 2012-03-31 |
$179 |
| 2011-12-31 |
$150 |
| 2011-09-30 |
$175 |
| 2011-06-30 |
$175 |
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
$178 |
| 2010-03-31 |
$129 |
| 2009-12-31 |
$90 |
| 2009-09-30 |
$102 |
| 2009-06-30 |
$114 |
| 2009-03-31 |
$123 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$49.143B |
$5.382B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
